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Hepatocyte growth factor ameliorates progression of interstitial
fibrosis in rats with established renal injury.
Background. Hepatocyte growth factor (HGF) has been re-
ported to prevent injury in several models of renal disease; how-
ever, whether HGF can also retard progression of established
renal disease is not known.
Methods. The aim of the present study was to examine the
effects of HGF on progression of chronic renal disease in rats
with remnant kidneys and established injury. Studies were per-
formed in rats that underwent subtotal nephrectomy, were ob-
served for two weeks without therapy, and then randomized to
receive HGF or vehicle by continuous infusion for an additional
two weeks.
Results. HGF administration was associated with a reduc-
tion in morphologic evidence of interstitial, but not glomerular
injury. The beneficial effects of HGF were not associated with
reductions in the expression of transforming growth factor-beta
(TGF-b), or in the extent epithelial cell apoptosis or transdif-
ferentiation. Rather, HGF appeared to induce fibrinolytic path-
ways by increasing expression of metalloproteinase-9 (MMP-9)
and decreasing levels of plasminogen activator inhibitor-1
(PAI-1) and tissue inhibitor of metalloproteinase-1 (TIMP-2).
HGF administration was also associated with an apparent in-
crease in renal endothelin production and a significant reduc-
tion in glomerular capillary pressure.
Conclusion. These findings suggest that HGF can retard pro-
gression of chronic renal disease even after injury is already
established, primarily by promoting matrix degradation.
Following subtotal nephrectomy, rats develop a syn-
drome of hypertension, proteinuria, and renal dysfunc-
tion that eventually leads to progressive glomerular
sclerosis, interstitial fibrosis, and end-stage renal failure
[1]. A number of factors have been proposed to ex-
plain progression in this model, including alterations in
glomerular hemodynamics [2], and/or in the production
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of various growth factors and cytokines that regulate
matrix production and degradation and, thereby, renal
scarring [3, 4]. However, exactly which factors are truly
important modulators of chronic renal disease progres-
sion are still uncertain.
Originally characterized as a potent mitogen for liver
cells, hepatocyte growth factor (HGF) has multiple ef-
fects on renal tubular epithelial cells, including stimula-
tion of cell proliferation, motility, and differentiation [5].
We reported that the HGF/c-met system is also activated
in remnant kidneys and that blockade of endogenous
HGF by administration of a specific antibody markedly
worsens kidney function and morphologic evidence of
renal injury in this model [6]. In that and other studies,
HGF was shown to have antifibrotic effects, including
blockade of epithelial to fibroblast transdifferentiation
and stimulation matrix degradative pathways [7–9]. Of
note, although HGF has now been reported to amelio-
rate injury in several models of renal disease [6–11], in
each instance, HGF was initiated either before or coin-
cident with the initial onset of injury. As a result, these
studies demonstrate that HGF can partially prevent re-
nal damage, but not that HGF can retard progression
of established renal disease. The purpose of this study
was to examine the effects of HGF on progression of
chronic renal disease in rats with remnant kidneys and
established injury. We found that administration of ex-
ogenous HGF not only reduced morphologic evidence
of interstitial injury but also had unsuspected effects on
glomerular hemodynamics. We also examined the effects
of HGF on a number of other parameters associated with
progression of chronic renal disease, including glomeru-
lar and tubular cell apoptosis, as well as the expression of
various cytokines, growth factors, and matrix-regulating
molecules.
METHODS
Design of the animal studies
All studies were approved by the Rhode Island Hos-
pital Institutional Animal Care and Use Committee and
409
410 Dworkin et al: HGF and interstitial fibrosis
performed in accordance with published guidelines. Stud-
ies were performed in two groups (N = 9 per group) of
male Sprague-Dawley rats with initial weights of 180–
240 g. To produce the remnant kidney model, rats un-
derwent right nephrectomy and segmental infarction of
approximately 2/3 of the left kidney by ligation of two to
three branches of the left main renal artery as previously
described [6]. To select rats with near uniform reductions
in renal mass, serum creatinine was measured three days
after ablation and only rats with a creatinine between 0.8
and 1.2 mg/dL were included. Rats were then followed for
two weeks without therapy, by which time hypertension
and proteinuria are present and morphologic evidence of
injury is already apparent [6].
Beginning two weeks after ablation, HGF or vehicle
(control) was continuously infused intravenously for two
weeks by implantation of an osmotic minipump. Rats
were anesthetized; a small incision was made over the left
jugular vein, which was then cannulated with polyethy-
lene tubing (PE50) connected to an osmotic pump (Alzet,
Cupertino, CA, USA) that delivered its contents at con-
stant rate of 0.5 lL/hr. Pumps were filled with recombi-
nant human HGF (Genentech, South San Francisco, CA,
USA) in saline in a concentration calculated to result in
an infusion rate of 20 lg HGF per day. Control rats re-
ceived pumps containing saline alone.
Micropuncture studies
Four weeks after ablation and two weeks after admin-
istration of HGF or vehicle, rats were anesthetized with
thiobutabarbital (100 mg/kg, intraperitoneally), placed
on a heated table, and prepared for micropuncture deter-
mination of the pressures, flows, and resistances govern-
ing glomerular ultrafiltration as described previously [12],
with minor modifications. Briefly, polyethylene catheters
were inserted into the femoral artery, left and right
jugular veins, and the left ureter for infusion of solu-
tions and collection of samples. A tracheostomy was per-
formed. Arterial pressure was continuously measured by
a pressure transducer connected to a computer running
WINDAS software (DATAQ Instruments, Inc., Akron,
OH, USA). All rats received isoncotic rat plasma at a
rate of 0.1 mL/min for a total of 10 mL/kg body weight,
followed by a sustained infusion of plasma at a rate of
0.5 mL/hr to compensate for surgical losses and spec-
imen collection. Rats also received a 0.5 mL bolus
and a sustained infusion (0.5 mL/hr) of [3H] inulin in
saline. Individual tubules were punctured using sharp-
ened glass pipettes. Tubular fluid, urine, and blood sam-
ples were collected for determination of single nephron
and whole kidney GFR by the measurement of 3H in-
ulin activity. Pressures were measured in cortical tubules
and efferent arterioles using the servo-null, micropipette
technique. Glomerular capillary pressure was estimated
using the stop-flow technique. Whole kidney renal plasma
flow (RPF) was measured after the conclusion of the mi-
cropuncture studies using an ultrasonic flow probe (Tran-
sonic Systems, Inc., Ithaca, NY, USA). In this technique,
the left renal artery was dissected away from the per-
inephritic fat and a flow probe placed around the renal
artery near the hilum of the kidney. The area around the
probe was infused with a viscous gel. The probe is con-
nected via a flow meter to a computer and renal blood
flow (RBF) recorded. Whole kidney filtration fraction
(FF) was calculated using the standard formula. Initial
glomerular capillary plasma flow rate was estimated us-
ing the measured values for single nephron glomerular
filtration rate (SNGFR) and whole kidney FF.
Determination of plasma HGF levels by ELISA
The plasma concentration of HGF was measured using
a specific sandwich enzyme-linked immunosorbent assay
(ELISA) kit (R&D Systems, Minneapolis, MN, USA) ac-
cording to the manufacturer’s instructions.
Morphologic techniques
At the conclusion of the hemodynamic studies, kid-
neys were perfused with iced saline and a portion of the
kidney fixed by immersion in formalyn. Coronal slices of
each kidney were stained with hematoxylin/eosin (HE).
Microscopic abnormalities were assessed in a blinded
fashion by a single observer. Glomerular and tubulointer-
stitial changes were individually assessed. For glomerular
changes, all glomeruli in a section (∼60–80) were exam-
ined. Each tuft received a score of 0–4 based on how many
quadrants were abnormal (0 = none; 4 = all). A compos-
ite glomerular score was obtained for each rat by adding
the scores for each glomerulus and dividing the total by
the number of glomeruli that were examined. Tubuloint-
erstitial damage was quantified in a similar fashion. Thirty
randomly selected fields were examined and graded 0–4
based on the percentage of the field that was abnormal
(0 = none, 1 = 25%, 2 = 50%, 3 = 75%, 4 = 100%).
The scores were added and divided by the number of
fields examined to produce a composite interstitial injury
score.
Immunohistochemistry
Alpha-smooth muscle actin (a-SMA), metal
metalloproteinase-9 (MMP-9), tissue inhibitor of
metalloproteinase-2 (TIMP-2), endothelin (ET-1),
and plasminogen activator inhibitor-1 (PAI-1) protein
levels were assessed in kidney sections by immuno-
histochemistry. Remnant kidneys were embedded in
paraffin, sliced, and mounted on glass slides. Staining for
a-SMA was performed using a monoclonal mouse anti-
a-SMA antibody (Cat. #A2547; Sigma Chemical Co.,
St. Louis, MO, USA) in appropriate buffer according
to Vectastain (Vector Laboratories, Burlingame, CA,
USA) anti-mouse ABC kit instructions. The following
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polyclonal antibodies were used to detect their specific
ligands: rabbit anti-MMP-9 antibody (Cat. #M-5302;
Sigma Chemical Co.), rabbit anti-TIMP-2 antibody (Cat.
#T-8062; Sigma Chemical Co.), rabbit anti-ET-1 antibody
(Cat. #PC266; Oncogene Research Products, Cambridge,
MA, USA), rabbit anti-PAI-1 antibody (Cat. #sc-8979;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), also
using the Vectastain ABC Kit. Slides were stained with
diaminobenzidine tetrahydro chloride (DAB) and coun-
terstained with methyl green or hematoxylin, cleared,
and mounted using Vectamount (Vector Laboratories)
permanent mounting medium. The extent of a-SMA
expression was assessed in a blinded fashion by a single
investigator. Fifteen fields per slide were examined,
scored from 0 to 3, and the field scores averaged to
generate a composite score for each animal. Expression
of other proteins was assessed semiquantatively and
results of these studies were presented as representative
images.
Determination of apoptosis score by TUNEL staining
Remnant kidneys embedded in paraffin were sec-
tioned onto glass slides. Dehydration was performed us-
ing xylene and ethanol in series as recommended by
the kit protocol. TUNEL staining was performed us-
ing the TdT-FragELTM DNA Fragmentation Detection
Kit (Cat. #QIA33; Oncogene Research Products). Detec-
tion of apoptotic cells and counter stain of sections were
produced using DAB (12 minutes) and methyl green
(3 minutes), respectively. The slides were mounted with
a coverglass using VectamountTM permanent mounting
medium. Glomerular and interstitial apoptosis scores
were individually assessed in a blinded fashion under 40×
magnification. The number of positive apoptotic bodies
in 20 randomly selected glomeruli from each section was
determined and an average glomerular apoptosis score
calculated for each rat. An interstitial apoptosis score was
calculated by counting the number of positive cells in 10
randomly selected interstitial fields per specimen.
Preparation of cDNA probe from kidney
A cortical section of the remnant kidney from each rat
was snap frozen in liquid nitrogen and stored at −80◦C.
Total RNA was extracted from homogenate of the renal
cortex using TRIzol (Invitrogen, Carlsbad, CA, USA),
and then treated with DNase I (Promega, Madison, WI,
USA) to eliminate potential contamination with resid-
ual genomic DNA. The cDNA was prepared from 2 lg
of the total RNA using SuperScript II RNase H-reverse
transcriptase (Invitrogen), followed by ethanol precipi-
tation with ammonium acetate to remove surplus dNTP.
The purified cDNA preparations from three rats in the
same group were pooled and the mixture was labeled
with 25 lCi [a-33P]dCTP (NEN Life Science Products,
Boston, MA, USA) using Random Primers DNA Label-
ing System (Invitrogen), followed by purification through
Sephadex G-50 (Amersham Biosciences, Piscataway, NJ)
spin column.
Dot-blot analysis
Genes of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), connective tissue growth factor (CTGF), vas-
cular alpha-smooth muscle actin (a-SMA), fibronectin,
HGF, hepatocyte growth factor receptor (c-met),
and TGF-b1 were amplified by reverse transcription-
polymerase chain reaction (RT-PCR) using specific
primers listed in Table 1. The PCR products were pu-
rified by precipitation with ethanol and ammonium ac-
etate. Each heat-denatured PCR product (25 ng/spot) was
applied in duplicate to positively charged nylon mem-
brane (Nytran Plus; Schleiger & Schuell, Keene, NH,
USA) using a vacuum dot blotting apparatus followed
by ultraviolet cross-linking. Strips of the dot blots were
preincubated in 100 mL hybridization bottles with 5 mL
of hybridization solution (0.5 mol/L NaHPO4, pH 7.2,
1 mmol/L EDTA, 7% SDS). After two hours of prehy-
bridization, 1 × 107 cpm of each 33P-labeled cDNA probe
was added to each membrane strip. After 16 hours of hy-
bridization with rotation at 17 rpm, the membrane strips
were rinsed with washing solution (40 mmol/L Na2HPO4,
1% SDS) and washed three times at 65◦C for 20 minutes
per wash. The membrane strips were plastic-wrapped and
exposed to BAS-MS2040 imaging plate (Fuji Photo Film
Co., Kanagawa, Japan) for 48 hours, and then the im-
age was processed by a BAS-2500 phosphoimager (Fuji
Photo Film Co.). Hybridization signal intensity of each
spot measured as photo-stimulated luminescence (PSL)
developed on the imaging plates were processed for
quantitative analysis using Array Vision imaging soft-
ware (IMAGING Research, Inc., St. Catharines, Ontario,
Canada).
Cell culture studies
To further examine the effects of HGF on matrix de-
grading pathways in kidney cells, human proximal tubular
cells were serum deprived for 24 hours, and then exposed
to HGF or control media in the presence of absence of
varying concentrations of angiotensin II. After 24 hours
of incubation, RNA was isolated from approximately 2 ×
106 human proximal tubular epithelial cell (HKC) cells
using TRIzol solution according to the instructions spec-
ified by the manufacturer. Briefly, cells grown in 6-well
plates were harvested in TRIzol and 200 lL chloroform
was added. After centrifugation for 15 minutes at 12,000g,
the aqueous phase was mixed with an equal volume of
isopropylalcohol. After 12 hours at −20◦C, the RNA was
pelleted for 15 minutes at 10,000g, washed twice with 70%
ethanol, dried, and dissolved in H2O. RNA was quantified
by measuring ultraviolet absorbance at 260 nm, its purity
documented by comparison of the ultraviolet absorbance
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Table 1. List of PCR primers
PCR product
Gene (Dot blot) 5′-Primer 3′-Primer size (bp)
Glyceraldehyde-3-phosphate- AACTTTGGCATCGTGGAAGG CCACCACCCTGTTGCTGTAG 478
dehydrogenase (GAPDH)
Transforming growth factor, beta 1 CGCGTGCTAATGGTGGAAAC CGGTAGTGAACCCGTTGATG 400
Connective tissue growth factor GGAGTGGGTGTGTGATGAGC TGTAATGGCAGGCACAGGTC 497
Vascular alpha-smooth muscle actin GAAGCGCAGAGCAAGAGAGG CCAGAGCGACATAGCACAGC 496
Fibronectin CGCTTTGACTTCACCACCAG GCCGTTTCAGGAAGGTTGAG 503
Hepatocyte growth factor AGGGCTTTCCATTCACTTGC CAAGAATTTGTGCCGGTGTG 506
c-met CCGAGGTTCACTGCATGTTC TACTGACATACGCGGCTTGG 507
Gene (RT-PCR)
MMP-9 5′-GAC TCG GTC TTT GAG GAG CC-3′(sense)
5′-GAA CTC ACG CGC CAG TAG AA-3′(antisense)
TIMP-2 5′-GTTTTGCAATGCAGATGTAG-3′(sense)
5′-ATGTCGAGAAACTCCTGCTT-3′(antisense)
PAI-1 5′-ACTACGACCGCGACAAGA-3′(sense)
5′-AGGTCAATGTCAGGAGAGGC-3′(antisense)
GAPDH 5′-GAAGGTGAAGGTCGGAGTC-3′(sense)
5′-GAAGATGGTGATGGGATTTC-3′(antisense)
readings at 260 and 280 nm, and its integrity assured by
documentation of intact ribosomal RNA bands on ethid-
ium bromide–stained agarose gels.
cDNA generation and RT-PCR
Total RNA harvested from HKC cells was diluted to
0.2 lg/lL in H2O and first-strand cDNA was prepared
using 5 lg of RNA, Superscript RT reverse transcrip-
tase and oligo(dT) primer according to the instructions
of the manufacturer. Reverse transcriptase was then in-
activated by heating at 70◦C for 15 minutes, and RNase
was added to remove the template RNA. Aliquots of
the cDNA were then amplified using specific primers
(Table 1). The housekeeping gene GAPDH served as an
internal control. PCR products were electrophoresed in
1.5% agarose gels containing 0.5 lg/mLof ethidium bro-
mide. Resolved gels were photographed under UV light
with Polaroid negative film (Polaroid, Cambridge, MA,
USA).
Statistics
Statistical analyses were performed using a personal
computer running SigmaStat 2.0 software (SPSS, Inc.,
Chicago, IL, USA). The Student t test was employed
to compare normally distributed data from control and
HGF-infused rats and the Mann-Whitney rank sum test
was used for nonparametric data. Data are presented as
mean ± SE.
RESULTS
Whole animal data
The average serum creatinine at day three after ab-
lation was 0.99 ± 0.03 for control rats and 0.97 ± 0.04
in HGF-treated rats. These values were not significantly
different. On average, rats gained weight from time of
ablation to time of sacrifice. At 4 weeks after ablation the
values for mean weight were identical, 271 ± 13 g in both
groups. ELISA determination of plasma HGF concentra-
tion after 2 weeks of constant infusion and immediately
before sacrifice demonstrated that rats receiving HGF
by minipump had about a threefold elevation in plasma
HGF level to 660 ± 147 pg/mL as compared to 231 ±
10 pg/mL in saline-infused, control rats (P < 0.05).
Micropuncture data
Results of the micropuncture studies are summarized
in Table 2. Although mean arterial pressure was not sig-
nificantly changed, infusion of HGF was associated with
a significant reduction in the glomerular capillary hy-
draulic pressure (PGC) of 14 mm Hg on average. Of note,
this magnitude of reduction in PGC is similar to that pro-
duced in this model by dietary protein restriction [13] or
by the administration of renin-angiotensin system block-
ing drugs [14], and has been associated with amelioration
of glomerular injury in these settings. There were no sta-
tistically significant changes in any other hemodynamic
parameter, including whole kidney or single nephron
plasma flow or GFR, or in the calculated values for affer-
ent or efferent arteriolar resistance.
Morphologic data
Representative light micrographs from control and
HGF-infused rats are shown in Figure 1. Typical glomeru-
lar and tubulointerstitial changes in the remnant kidney
model have been previously described [13] and include,
within the glomerulus, hypertrophy, microaneurysm, and
microthrombus formation, mesangial expansion, seg-
mental and global sclerosis. Interstitial changes typically
correlate with glomerular lesions and include tubular di-
latation, cast formation, interstitial collagen deposition,
and fibrosis. The severities of glomerular and interstitial
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Table 2. Results of the micropuncture study
mL/min mm Hg
MAP FF CA
Group mm Hg GFR RPF % PGC PT P g/dL
Control N = 12 169 ± 8 0.51 ± 0.10 3.4 ± 1.2 0.18 ± 0.02 71 ± 3 15 ± 1 56 ± 3 5.8 ± 0.2
HGF N = 9 151 ± 12 0.47 ± 0.13 2.9 ± 0.3 0.15 ± 0.03 57 ± 3 13 ± 1 44 ± 3 5.5 ± 0.1
NS NS NS NS <0.01 NS <0.02 NS
dyne∗s∗cm−5 × 1010
SNGFR Kf
nL/min QA nL/smm Hg RA RE RA/RE
113 ± 7 677 ± 108 0.059 ± 0.005 0.51 ± 0.09 0.29 ± 0.05 1.79 ± 0.12
92 ± 8 831 ± 207 0.069 ± 0.008 0.48 ± 0.13 0.22 ± .0.07 2.45 ± 0.24
= 0.07 NS NS NS NS <0.02
N, number per group. Values are mean ± SE. Abbreviations are: NS, not significantly different; MAP, mean arterial pressure; GFR, glomerular filtration rate; RPF,
renal plasma flow; FF, filtration fraction; PGC, glomerular capillary pressure; PT, proximal tubular pressure; P, glomerular transcapillary hydraulic pressure difference;
CA, plasma protein concentration; SNGFR, single nephron glomerular filtration rate; QA, initial glomerular capillary plasma flow rate; Kf, ultrafiltration coefficient;
RA, afferent arteriolar resistance; RE, efferent arteriolar resistance.
A B
Fig. 1. Representative light micrographs of
kidney cortex from a remnant kidney from
a control rat that received vehicle (A) as
compared to a rat that received intravenous
hepatocyte growth factor (HGF) (B) for two
weeks. The kidney in (A) shows the typical
findings in remnant kidneys at 4 weeks after
ablation including glomerular sclerosis, inter-
stitial inflammation, tubular atrophy, and cast
formation. Although some interstitial inflam-
mation is observed, glomerular and tubular
architecture are better preserved in the HGF-
treated rat (B). (PAS, × 40).
changes were scored separately and are presented in
Figure 2. Glomerular lesions tended to be less extensive
in HGF-treated rats, although the difference was not sig-
nificantly different. However, the interstitial injury score
was significantly reduced by approximately 50% by HGF
administration.
Immunohistochemistry
One purported mechanism by which HGF reduces in-
terstitial fibrosis is by inhibiting transdifferentiation of
renal epithelial cells to a fibroblastic phenotype. These
interstitial fibroblasts are hypothesized to be major pro-
ducers of interstitial matrix material, thereby contribut-
ing to progression of interstitial fibrosis. To determine
the extent of epithelial transdifferention, remnant kid-
neys were stained with a specific anti-a-SMA antibody.
The results of these studies are summarized in Figure 3.
In the normal kidney, anti-a-SMA staining is essen-
tially limited to vascular profiles and Bowman’s capsule
with little or no protein detected in renal tubular cells
(Fig. 3A). In contrast and shown in Figure 3B, much
more extensive staining is detected in remnant kidneys
and not only vessel walls, but also many tubule cells are
positive. However, when sections from control and HGF-
infused rats were scored and compared, no reduction in
anti-a-SMA staining was observed in the HGF-treated
group.
Representative micrographs from the immunohisto-
chemical assessment of renal cortical endothelin, TIMP-
2, PAI-1, and MMP-9 expression are presented in
Figure 4. Administration of HGF was associated with
induction of endothelinf expression in distal tubule pro-
files and particularly in those adjacent to the glomerulus
in the region of the juxtaglomerular apparatus (Fig. 4B).
Endothelin was also present in these segments in rem-
nant kidneys from rats not given HGF, but staining was
less intense. Shown in Figure 4 D and F, respectively, ex-
pression of TIMP-2 and PAI-1 was suppressed in HGF-
treated rats, as compared to control remnant kidneys (Fig.
4 C and E). In contrast, expression of the matrix degrad-
ing metalloproteinase MMP-9 was markedly induced by
HGF (Fig. 4H) as compared to untreated rats (Fig. 4G).
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Fig. 2. Glomerular and tubulointerstitial injury scores in control and
hepatocyte growth factor (HGF)-treated remnant rats. There was a sig-
nificant reduction in interstitial injury in the HGF group. CON, control
rat; HGF, HGF-infused rat; –G, glomerular injury score; –I, interstitial
injury score.
Effects of angiotensin II and HGF on matrix-regulating
genes in HKC cells
Results of the cell culture studies are summarized in
Figure 5. Evidence suggests that activation of the renin-
angiotensin system is a key event driving progression of
chronic renal disease in remnant kidneys. Consistent with
this hypothesis, incubation of HKC cells with angiotensin
II was associated with increased levels of TIMP-2 and
PAI-1, both changes tending to promote fibrosis by in-
hibiting matrix degradation. MMP-9 levels were not sig-
nificantly affected by Ang II in HKC. Consistent with
the immunostaining results in remnant kidney tissue, this
Ang II–induced, profibrotic milieu was reversed by HGF,
which reduced mRNA levels for TIMP-2 and PAI-1 and
increased expression of MMP-9 in both control and Ang
II–treated cells.
Apoptosis score
Another mechanism by which HGF might preserve
normal kidney structure is by inhibiting dropout of nor-
mal kidney cells caused by apoptosis. To assess the effects
of HGF on glomerular and tubular apoptosis, the mean
numbers of apoptotic bodies in glomeruli and in the cor-
tical tubulo-interstitium in control and HGF-treated rats
were determined and are presented in Figure 6. Shown
in Figure 6A, on average, less than one apoptotic body
was observed per remnant glomerulus, and this number
was not significantly altered by HGF. Shown in Figure 6B,
approximately 20 apoptotic bodies were observed in ran-
domly selected tubulointerstitial fields in control remnant
kidneys; however, this number was also not significantly
altered by HGF.
Gene expression studies in kidney tissue
To further examine the mechanism by which HGF
ameliorated injury, we measured relative RNA levels
(normalized for expression of GAPDH) of connective
tissue growth factor (CTGF), TGF-b , HGF, c-met, fi-
bronectin, and a-SMA in kidney cortex from control and
HGF-treated remnant rats. These data are summarized in
Figure 7. Neither CTGF, TGF-b , HGF, c-met, fibronectin,
nor aSMA mRNA levels were significantly altered in cor-
tical tissue of remnant rats by administration of HGF. Of
note, the similar mRNA levels for a-SMA by dot blot are
consistent with the histochemical data, which also failed
to demonstrate a significant reduction in a-SMA protein
in the tubules and interstitium of HGF-treated rats.
DISCUSSION
One important finding in the current study is that
continuous administration of a low dose of exogenous
HGF for two weeks significantly reduced morphologic
evidence of interstitial injury in the rat remnant kidney.
This finding is consistent with our previous study [6], in
which blockade of endogenous HGF in vivo by provision
of a high-titer anti-HGF antibody significantly exacer-
bated injury in this model. These data suggest that HGF
is beneficial in chronic renal disease, tending to reduce
interstitial damage. Consistent with this view, exogenous
HGF has also been shown to lessen injury in the ICGN
mouse model of progressive interstitial fibrosis [11, 15].
Similarly, mice injected with a naked plasmid containing
the human HGF gene displayed increased hepatic pro-
duction of HGF and were protected from developing in-
terstitial fibrosis after unilateral ureteral obstruction [8].
However, not all studies have demonstrated a beneficial
effect of HGF on chronic renal injury. For example, in one
strain of transgenic mice that overexpress HGF, progres-
sive renal injury characterized by cyst formation, tubular
hyperplasia, and glomerular sclerosis developed [16]. Po-
tentially more relevant, Laping et al [17] reported that
administration of HGF to a strain of obese diabetic mice
was associated with a reduction in creatinine clearance
and an increase in albumin excretion. The explanation
for these divergent results in different models of chronic
renal disease is uncertain, but may have resulted from
differences in the species, strain, or type of renal disease
studied, or from variation in the duration, amount, and/or
route of administration of HGF.
Multiple mechanisms by which HGF might ameliorate
chronic renal injury have been proposed. Progression
to end-stage renal disease is a process in which normal
kidney cells die off and are replaced by fibrous tissue.
Whereas necrosis is a major cause of cell death in acute
renal injury, apoptosis has been repeatedly observed [10,
18] and probably accounts for a significant fraction of
kidney cell loss in chronic kidney disease. It follows that
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BA
Fig. 3. Alpha-smooth muscle actin (a -SMA)
expression in normal (A) and remnant (B)
kidney cortex. In normal kidney, a-SMA ex-
pression is limited to vascular profiles. In con-
trast, in the remnant kidney, a-SMA expres-
sion is observed not only in the vascular tissue,
but in tubular cells as well (asterisks) and in
the peritubular interstitium. See Methods for
details.
one mechanism by which HGF might ameliorate injury
is by inhibiting apoptosis of tubular cells. Consistent with
this view, HGF prevents renal epithelial cells from under-
going apoptotic cell death following exposure to various
toxins [19, 20]. However, in the current study, we were
unable to demonstrate any reduction in apoptosis in the
kidneys of rats given HGF by TUNEL staining. This sug-
gests that the beneficial effect of HGF on progression of
chronic disease does not depend primarily on enhanced
cell survival.
Alternatively, we have suggested that HGF may slow
progression of chronic renal disease by reducing accu-
mulation of extracellular matrix [6]. Against this hypoth-
esis, HGF directly stimulates production of individual
matrix proteins such as fibronectin by epithelial cells
[5]. However, matrix accumulation leading to tissue fi-
brosis is a complex process involving multiple cell types
and alterations in both matrix synthesis and degradation.
Potentially relevant to progressive interstitial fibrosis in
chronic kidney disease is the process of transdifferention,
by which renal epithelial cells convert to a more fibroblas-
tic phenotype. Epithelially derived interstitial fibroblasts
are thought to be the major source of the excess matrix
material that accumulates during progressive interstitial
fibrosis [21]. Transdifferentiation in vivo can be tracked
by examining the expression of a-SMA, a protein not pro-
duced by renal epithelial cells under normal conditions,
but abundantly expressed in epithelial cells undergoing
transdifferentiation into fibroblasts. To investigate the ef-
fects of HGF on transdifferentiation in the current study,
a-SMA expression was examined in control and HGF-
treated remnant rats by RT-PCR and by immunohisto-
chemistry. As previously reported, tubular expression of
a-SMA was readily detected in remnant kidneys; how-
ever, this was not reduced by HGF.
The failure of HGF to suppress epithelial transdiffer-
entiation in the current study is surprising and appears
inconsistent with previous reports [9, 21]. One possi-
ble explanation for these divergent results relates to the
marked induction of endogenous HGF observed in this
setting. HGF levels increase significantly in remnant as
compared to control rats, possibly resulting in full recep-
tor occupancy and near maximal activation of the HGF/c-
met axis at some sites [6]. If so, then further elevation in
circulating HGF levels by provision of exogenous HGF
might have little effect. It should be noted, however, that
the dose we administered was sufficient to suppress inter-
stitial injury, even though extent of transdifferentiation
was unaffected. It seems more likely that the failure of
HGF to suppress transdifferentiation relates to the tim-
ing of administration of the growth factor. In previous
studies of the effects of HGF in models of chronic renal
injury, HGF therapy has been initiated before, or at the
very latest, concurrent with, the onset of injury. There-
fore, in these studies, epithelial transdifferentiation was
prevented but not reversed. In contrast, in the current
study, injury was allowed to progress for two to three
weeks before the onset of HGF administration. In this
setting, a significant number of epithelial cells may have
already undergone transdifferentiation and HGF might
be unable to reverse this process. If this hypothesis is cor-
rect, then the clinical relevance of this particular action of
HGF is likely to be marginal, as chronic renal disease is
always well established before the initiation of any ther-
apy to slow progression. In any event, it seems apparent
that the reduction in interstitial injury we observed in
HGF-treated remnant rats did not depend on inhibition
of transdifferentiation.
Mizuma et al [15] suggested that HGF prevents fibrosis
by suppressing production of fibrogenic cytokines such
416 Dworkin et al: HGF and interstitial fibrosis
A B
C D
E F
G H
Fig. 4. Representative immunohistochemistry micrographs from remnant kidney cortex of rats that received vehicle (A, C, E, G) or hepatocyte
growth factor (HGF) (B, D, F, H). (A and B) demonstrate that administration of HGF induces the expression of endothelin in tubules (asterisks
and arrows) and in the juxtaglomerular apparatus (arrows in B). The expression of tissue inhibitor of metalloproteinase (TIMP)-2 (C and D) and
plasminogen activator inhibitor-1 (PAI-1) (E and F) are decreased in the tubulointerstitial (arrows) compartment of remnant kidneys by HGF. (G
and H) show that expression of metalloproteinase-9 (MMP-9) was significantly increased in HGF-treated rats in epithelial cells in both glomeruli
and tubules (arrow and asterisks). See Methods for details.
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Fig. 5. Effects of angiotensin II (Ang II) and hepatocyte growth factor
(HGF) on mRNA levels of plasminogen activator inhibtor-1 (PAI-1),
tissue inhibitor of metalloproteinase (TIMP)-2, and metalloproteinase-
9 (MMP-9) in human proximal tubular epithelial cell (HKC) cells. HKC
cells were treated with Ang II at 10−7or 10−6 mol/L in the presence or
absence of HGF (20 ng/mL) for 24 hours. Total RNA was extracted and
mRNA expression determined by semiquantitative polymerase chain
reaction (PCR) (N = 6). GAPDH expression served as a control. Ang
II induced expression of PAI-1 and TIMP-2, but not MMP-9, and this
was attenuated by HGF.
as TGF-b . To test this hypothesis, we assessed TGF-b
expression by RT-PCR. Unlike Mizuma et al [15], we
failed to detect any effect of HGF on TGF-b expression
in remnant rats and it seems unlikely that this played an
important role in the current study. Again, the failure of
HGF to suppress TGF-b in our study may result from
the fact that HGF was administered to rats well after the
onset of injury. Thus, HGF may prevent the initial rise in
TGF-b but it does not suppress TGF-b expression once
it has been induced.
One explanation for the beneficial effects of HGF on
interstitial injury in our study is suggested by the immuno-
histochemistry studies examining various molecules that
participate in matrix degradation. We found that expres-
sion of MMP-9 was markedly induced by HGF in remnant
kidneys. This finding is consistent with our previous ob-
servation that HGF could induce MMP-9 expression in
cultured human renal epithelial cells [6]. HGF induction
of MMP-9 was also associated with measurable suppres-
sion of the profibrotic molecules TIMP-2 and PAI-1. Plas-
minogen is an important activator of metalloproteinases,
and suppression of PAI-1 is associated with increased ac-
tivity of plasminogen and its substrate, inactive metal-
loproteinases. TIMPs inhibit metalloproteinase activity,
and suppression of TIMP-2 should also lead to increased
activity of MMP-9 and, potentially, other proteinases as
well. Therefore, the changes in the levels of these pro-
teins we observed in HGF-treated rats are predicted to
enhance matrix degradation, tending to retard matrix ac-
cumulation and progressive fibrosis.
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Fig. 6. (A and B) Apoptosis scores in glomeruli and tubules from rem-
nant rats. There was no significant reduction in apoptosis in response
to hepatocyte growth factor (HGF) in either glomeruli or in the tubu-
lointerstitial compartment. See Methods for details.
It should be noted that while immunostaining is ex-
tremely helpful in determining the site of increased gene
expression in tissue sections, it is a semiquantitative tech-
nique that fails to provide precise information on the
magnitude of increase in protein levels. Unfortunately, we
lacked sufficient tissue to confirm the increase in kidney
tissue expression by another technique, such as Western
blotting. However, studies using this technique may also
be misleading in a complex tissue such as kidney, which
contains a variety of cell types that may not all be affected.
Also, Western blotting may be too insensitive to detect
important changes in the production of proteins that are
not major cell products. Therefore, in order to provide fur-
ther evidence that HGF could induce significant changes
in MMP-9, TIMP-2, and PAI-1 in kidney cells, we exam-
ined the effects of HGF on mRNA levels for these pro-
teins in cultured renal epithelial cells by PCR. Studies
were performed in control cells and in cells that were ac-
tivated by incubation with Ang II. Ang II was selected
because of the dramatic effects of renin-angiotensin
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Fig. 7. Gene expression analysis profiles by dot blot of remnant kidneys
from saline and hepatocyte growth factor (HGF)-infused rats. Each
gene was blotted in duplicate. Quantitative hybridization units (PSL)
normalized relative to the housekeeping gene GAPDH are presented.
HGF failed to significantly alter the expression of any of the genes tested
in this analysis.
system blockade to reduce injury in this model [14], as
well as based on data that suggests that Ang II promotes
injury by inhibiting matrix degradation [3]. We found that
Ang II did induce PAI-1 and TIMP-2, although MMP-9
gene expression was not significantly altered. Importantly
and consistent with our in vivo studies, HGF reversed
these changes and also induced MMP-9 in HKC cells,
all tending to enhance matrix degradation and suppress
tissue fibrosis.
One unexpected observation in these studies was that
administration of HGF significantly altered glomerular
hemodynamics, producing on average a 14 mm Hg reduc-
tion in glomerular capillary pressure. This magnitude of
reduction in PGC is comparable to that observed with di-
etary protein restriction or with administration of agents
that block the renin-angiotensin-aldosterone system [13,
14] and, by analogy, potentially relevant to injury in this
model. Interestingly, there were no significant differences
in any other hemodynamic parameter between the two
groups; however, the reduction in glomerular pressure
seemed to depend on two factors. The first was a mod-
est reduction mean arterial pressure of about 8 mm Hg.
This difference was not statistically significant, in large
part due to the variability in blood pressure commonly
observed in remnant rats that are consistently hyperten-
sive but not uniformly so. The other factor contribut-
ing to the decline in PGC with HGF was about a 25%
increase in the ratio of afferent to efferent arteriolar
resistance in this group. Relative increases in afferent ar-
teriolar resistance, upstream to the glomerular capillaries,
are predicted to be associated with a decline in glomerular
capillary pressure. Once again, the difference in the ratio
of RA to RE between control and HGF rats was not statis-
tically significant but may nevertheless have been biologi-
cally important. To note, arteriolar resistance as assessed
by micropuncture is a parameter that requires input of
five separate measured quantities. As a result, variance in
this parameter can be relatively large, making it difficult
to detect relatively small changes in the values of these
resistances.
The exact mechanism of the increase in preglomeru-
lar resistance in HGF-treated rats is not clear from these
studies and requires further investigation. The HGF re-
ceptor c-met is present on both vascular endothelial [22,
23] and vascular smooth muscle cells [24]; however, a di-
rect vasoconstrictor effect of HGF on vascular smooth
muscle has not been demonstrated and seems unlikely.
Alternatively, HGF might act secondarily by altering the
activity of another vasoactive system. Consistent with
this hypothesis, we detected increased immunostaining
for endothelin in kidney sections of HGF-treated rats as
compared to control rats. Increased endothelin expres-
sion was seen in glomeruli, but was most evident in dis-
tal tubule elements, including the macular densa region,
which is immediately adjacent to the vascular pole of the
glomerulus and ideally situated to alter afferent arteriolar
resistance. To note, preliminary data from our laboratory
suggests that pretreatment with an endothelin receptor
antagonist can prevent an HGF-induced alterations in
glomerular hemodynamics in normal rats [25].
It is unclear if the reduction in glomerular pressure we
observed accounted for the reduction in injury in rem-
nant rats receiving HGF. Although the magnitude of the
decline was significant and similar to that observed with
angiotensin-converting enzyme (ACE) inhibitors in this
model that are also protective, morphologic evidence of
glomerular injury was not significantly reduced. Unfortu-
nately, proteinuria, which might be predicted to decline
in response to a reduction in glomerular pressure, was
not assessed. In fact, the major beneficial effects of HGF
on kidney morphology were seen in the tubulointersti-
tial compartment. If the reduction in PGC were respon-
sible for preservation of structure in this study, then one
would have expected that glomerular injury would also
have been significantly ameliorated.
CONCLUSION
Intravenous administration of HGF reduced morpho-
logic evidence of interstitial injury in rats with remnant
kidneys. This effect was not explained by alterations in
the extent of apoptosis, kidney expression of TGF-b , or
in epithelial cell transdifferentiation. Instead, HGF ad-
ministration was associated with increased expression of
MMP-9 and decreased levels of PAI-1 and TIMP-2, all
tending to promote matrix degradation. HGF infusion
also caused glomerular pressure to decline significantly,
possibly by augmenting endothelin levels leading to a rel-
ative increase in afferent arteriolar resistance. However,
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further studies are needed to determine the mechanism
by which HGF alters renal hemodynamics in this setting.
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